Company Overview: HRTX

Upcoming Projects (HRTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (HRTX)

Following up after the Launch of Zynrelef, following its approval in May 2021 as post-surgical analgesia and it's recent label expansion (December 2021)
Ticker: HRTX
Executed On: Apr 26, 2022 at 05:00 PM EDT

Expired Projects (HRTX)

Discussing Heron Therapeutics’ APONVIE (aprepitant / HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV), following FDA Approval
Ticker: HRTX
Execute By: Nov 09, 2022

Upcoming & Overdue Catalysts (HRTX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (HRTX)

Heron Therapeutics' (HRTX) HTX-011 in Post operative pain PDUFA date set for May 12, 2021
Ticker: HRTX
Occurred on: May 12, 2021
Heron Therapeutics (HRTX) Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
Ticker: HRTX
Occurred on: Jun 29, 2020
Heron (HRTX) Files New Drug Application with FDA in 2H 2018 for HTX-011 in Post-Operative Pain
Ticker: HRTX
Occurred on: Jun 21, 2018
Topline Results From Pivotal Phase 3 Clinical Trials of Heron Therapeutics'(HRTX) HTX-011 in Bunionectomy and Hernia Repair
Ticker: HRTX
Occurred on: Mar 19, 2018
Heron (HRTX) Expects Commercial Launch of Cinvanti in Q1 2018 for Patients with Chemotherapy-Induced Nausea & Vomiting (CINV)
Ticker: HRTX
Occurred on: Jan 04, 2018
Heron (HRTX) Expects FDA Decision on November 12th, 2017 for Cinvanti (HTX-019) in Treatment of Chemotherapy-Induced Nausea & Vomiting (CINV)
Ticker: HRTX
Occurred on: Nov 09, 2017
Heron (HRTX) Plans to Initiate Phase 3 Studies in 2017 Evaluating HTX-011 in Post-Operative Pain
Ticker: HRTX
Occurred on: Aug 09, 2017
Heron (HRTX) Expects to Initiate Phase 2 Program in Early Q1 Evaluating HTX-011 in Post Operative Pain in Nerve Block
Ticker: HRTX
Occurred on: May 10, 2017
Heron (HRTX) Announces SUSTOL ER Injection Now Included in National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017
Ticker: HRTX
Occurred on: Feb 24, 2017
NDA filing of HTX-019 for the prevention of chemotherapy-induced nausea and vomiting (CINV) due 2H 2016
Ticker: HRTX
Occurred on: Jan 12, 2017
Heron Therapeutics (HRTX) Announces Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty
Ticker: HRTX
Occurred on: Jan 04, 2017
Heron (HRTX) Expects to Release Top-Line Data in Early Q1 from Phase 2 Study 203 Evaluating HTX-011 in Pain Management Following Abdominoplasty
Ticker: HRTX
Occurred on: Jan 04, 2017
Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek 2016
Ticker: HRTX
Occurred on: Sep 08, 2016
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Ticker: HRTX
Occurred on: Aug 10, 2016
Heron Therapeutics Enters into Loan Agreement for Up to $100 Million; The loan will have a two-year term and bear interest of 8% per annum
Ticker: HRTX
Occurred on: Aug 02, 2016
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain
Ticker: HRTX
Occurred on: Aug 01, 2016
PDUFA January 17 2016 for resubmission of APF530 - Sustol, for prevention of acute and delayed-onset cheemotherapy-induced nausea and vomiting (CINV)
Ticker: HRTX
Occurred on: Apr 18, 2016
Heron Therapeutics Notified by FDA That It Will Not Take Action on SUSTOL New Drug Application by the PDUFA goal date of January 17, 2016, and anticipates taking action in late February 2016.
Ticker: HRTX
Occurred on: Mar 03, 2016

Strategic Initiatives (HRTX)

Don’t see a strategic initiative related to the company you care about? Create your own!

HRTX Overview